Q126 sees renewed strategy underway

Mendus’s Q126 results were in line with expectations, reflecting continued execution of its renewed clinical strategy for vididencel, with the key highlight being the transition to the clinic in chronic myeloid leukaemia (CML). The first patients have been recruited for the Phase I VITAL-CML trial, and an interim readout is expected in H226. If supportive, this will trigger the launch of the subsequent planned Phase II VITAL-TFR trial, potentially within the same year. For vididencel in acute myeloid leukaemia (AML), Mendus plans to launch the Phase Ib DIVA study in mid-2026, while the CADENCE trial is on track to enrol the first 20 patients within H126, which will be followed by an interim readout. Data from CADENCE and DIVA will guide...